Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) related to the company's US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan, resulting in an increase in the notional allocation of American Depositary Shares (ADSs) on February 1, 2013, at a price of $45.68 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c) regarding the notification of the following transactions:
- Dr M M Slaoui: 19 ADSs allocated.
- Dr K Slaoui (Connected Person): 2 ADSs allocated.
- Mr W C Louv: 9 ADSs allocated.
Investor Verification Checklist
- Verify the ADS price of $45.68 used for the notional allocation on February 1, 2013.
- Confirm the total number of ADSs allocated to the named directors and connected persons.
- Review the US Retirement Savings Plan rules regarding notional investments in GSK ADSs.